Popular Trials
Antibiotic
Minocycline + Amiodarone for Atrial Fibrillation
This trial will test whether or not minocycline, a safe and common acne drug, is better at preventing atrial fibrillation than amiodarone, the current standard of care. If minocycline is found to be more effective, it could be incorporated into clinical care for this disease, improving outcomes and reducing costs.
Anticoagulant
Edoxaban for Atrial Fibrillation
This trial is testing if edoxaban, a daily blood-thinning medication, can safely reduce stroke risk in high-risk atrial fibrillation patients who have had previous brain bleeds. The goal is to see if it works better than not using any blood thinners or using simpler treatments. Edoxaban has been shown to be effective in preventing stroke with a lower risk of bleeding.
Procedure
Cryoablation + LAA Closure for Atrial Fibrillation
This trial is testing a new heart surgery technique that uses a freezing device to create scar tissue to block off abnormal electrical pathways in the heart, in addition to sealing off the left atrial appendage to prevent blood clots.
Popular Filters
Trials for Stroke Patients
Anticoagulant
Anticoagulation for Atrial Fibrillation Post-Ablation
This trial is comparing medical approaches for stroke prevention in people who have atrial fibrillation (AF) and have undergone a successful procedure called ablation to eliminate or substantially reduce the arrhythmia.
Blood Collection Device Validation for Patients on Blood Thinners
This trial is for a medical device manufacturer to qualify their line of blood collection tubes with the FDA. Participants who are currently on anticoagulants will be compensated for their time and resources.
Anticoagulant
Anticoagulation + Antiplatelet Therapy for Post-Operative Atrial Fibrillation
This trial is looking at whether adding oral anticoagulation to background antiplatelet therapy is effective and safe in preventing thromboembolic events in patients who develop new-onset atrial fibrillation after isolated coronary artery bypass graft surgery.
Anticoagulant
Blood Thinners for Atrial Fibrillation
This trial is testing whether taking blood-thinning pills can prevent strokes and other heart issues in patients who have temporary irregular heartbeats and are at risk of stroke after surgery. These pills are a recent breakthrough in preventing strokes.
Anticoagulant
Apixaban vs Aspirin for Stroke Prevention in Atrial Fibrillation After Brain Bleed
This trial is testing whether apixaban is better than aspirin at preventing strokes or death in patients who have recently had a bleed in the brain and also have atrial fibrillation.
Trials for Ischemic Stroke Patients
Anticoagulant
Anticoagulation for Atrial Fibrillation Post-Ablation
This trial is comparing medical approaches for stroke prevention in people who have atrial fibrillation (AF) and have undergone a successful procedure called ablation to eliminate or substantially reduce the arrhythmia.
Anticoagulant
Anticoagulation + Antiplatelet Therapy for Post-Operative Atrial Fibrillation
This trial is looking at whether adding oral anticoagulation to background antiplatelet therapy is effective and safe in preventing thromboembolic events in patients who develop new-onset atrial fibrillation after isolated coronary artery bypass graft surgery.
Anticoagulant
Blood Thinners for Atrial Fibrillation
This trial is testing whether taking blood-thinning pills can prevent strokes and other heart issues in patients who have temporary irregular heartbeats and are at risk of stroke after surgery. These pills are a recent breakthrough in preventing strokes.
Anticoagulant
Apixaban vs Aspirin for Stroke Prevention in Atrial Fibrillation After Brain Bleed
This trial is testing whether apixaban is better than aspirin at preventing strokes or death in patients who have recently had a bleed in the brain and also have atrial fibrillation.
Device
Left Atrial Appendage Occlusion vs. NOAC for Atrial Fibrillation
This trial is looking at whether the Amulet LAA occluder is safe and effective compared to NOAC therapy in patients with non-valvular AF who are at increased risk for ischemic stroke and who have been recommended for long-term NOAC therapy.
Phase 3 Trials
Anticoagulant
Anticoagulation + Antiplatelet Therapy for Post-Operative Atrial Fibrillation
This trial is looking at whether adding oral anticoagulation to background antiplatelet therapy is effective and safe in preventing thromboembolic events in patients who develop new-onset atrial fibrillation after isolated coronary artery bypass graft surgery.
Anticoagulant
Apixaban vs Aspirin for Stroke Prevention in Atrial Fibrillation After Brain Bleed
This trial is testing whether apixaban is better than aspirin at preventing strokes or death in patients who have recently had a bleed in the brain and also have atrial fibrillation.
Monoclonal Antibodies
Abelacimab for Atrial Fibrillation
This trial is testing abelacimab, a medication aimed at preventing strokes and blood clots in people with Atrial Fibrillation. These patients are either unsuitable for or have chosen not to use common medications for thinning blood. Abelacimab works by reducing the blood's ability to form dangerous clots.
Behavioural Intervention
Colchicine for Atrial Fibrillation Recurrence After Ablation
This trial is investigating the role of colchicine in preventing atrial fibrillation (Afib) after an ablation procedure. Previous studies have shown that colchicine can lead to decreased recurrence of post-ablation Afib with a beneficial impact in self-perceived quality of life of the patients.
Trials With No Placebo
Behavioural Intervention
Exercise Training for Atrial Fibrillation
This trial will compare the effects of high-intensity interval training vs. moderate-intensity continuous exercise training in adults with persistent or permanent atrial fibrillation on exercise capacity and quality of life.
Procedure
Ablation Techniques for Atrial Fibrillation
This trial compares two methods of treating atrial fibrillation: one using a special technique to find specific problem areas in the heart and one without it. It targets patients whose condition hasn't improved with medication. The special technique aims to make the treatment more precise and effective.
Anticoagulant
Anticoagulation for Atrial Fibrillation Post-Ablation
This trial is comparing medical approaches for stroke prevention in people who have atrial fibrillation (AF) and have undergone a successful procedure called ablation to eliminate or substantially reduce the arrhythmia.
View More Related Trials
Frequently Asked Questions
Introduction to afib
What are the top hospitals conducting afib research?
When it comes to the ongoing battle against atrial fibrillation (afib), several top hospitals are leading the way in clinical trials. One such institution is Massachusetts General Hospital, located in Boston. With nine active afib trials and a remarkable 61 completed trials throughout their history, they have been at the forefront of tackling this cardiac condition since recording their first trial in 2003. Moving north to Canada, the University of Ottawa Heart Institute has emerged as another key player in afib research. This renowned institute boasts nine ongoing trials along with 29 previously conducted studies since initiating their inaugural trial back in 2000.
Meanwhile, at Montreal Heart Institute, also situated within Canada's vibrant medical landscape, researchers are actively engaged in six clinical trials focused on afib while having accomplished an impressive tally of 26 previous investigations dating back to their initial trial in 2000. In Birmingham's Grandview Medical Center, innovative efforts continue with six active afib trials building upon a foundation laid down by nineteen earlier endeavors that commenced only eight years ago with their initiation into conducting ground-breaking inquiries surrounding atrial fibrillation.
Lastly yet significantly worth mentioning is Cleveland Clinic located within Ohio which presently embarks five distinct atrial fibrillation studies contributing towards pathbreaking advancements whilst carrying out twenty-eight prior investigations; theirs can be traced all way through two decades starting from ancient1999.
These esteemed hospitals represent pillars of hope for those grappling with atrial fibrillation and showcase how medical professionals across borders are unitedly working towards unraveling mysteries around this condition. By being involved not just within respective local communities but also global scientific community these institutions bring together diverse expertise paving paths ahead improving lives worldwide
Which are the best cities for afib clinical trials?
In the realm of afib clinical trials, several cities emerge as leaders in research and development. New york, New York tops the list with 28 active trials investigating treatments like Pulse Field Ablation and WATCHMAN FLX Implant. Montreal, Quebec follows closely behind with 23 ongoing studies focusing on interventions such as Catheter ablation and Apixaban. Meanwhile, Boston, Massachusetts boasts 21 active trials exploring options like Antiplatelet Therapy and Left Atrial Appendage Occlusion. Lastly, Toronto, Ontario and Ottawa, Ontario contribute to this vital research field with their respective 20 and 18 active trials examining a range of potential therapies for afib patients. These cities serve as beacons of hope for individuals seeking innovative approaches to manage atrial fibrillation effectively
Which are the top treatments for afib being explored in clinical trials?
Exciting advancements are being made in the realm of afib treatments, with several notable contenders taking center stage in ongoing clinical trials. Intervention leads the pack with four active trials and an impressive track record of two all-time afib trials since its initial listing in 2012. Following closely behind is apixaban, showing promise with two active trials and a substantial history of 47 all-time afib trials dating back to 2007. Catheter ablation also holds its own, participating in two current studies and boasting a considerable presence with 28 all-time afib trials since its introduction in 2009. Amiodarone proves itself as another worthy contender, engaging in two active clinical trials while accumulating an impressive tally of 34 all-time afib trials starting from1998. Additionally, a novel approach through a twelve-week supervised exercise-based cardiac rehabilitation program has shown potential demonstrated by one ongoing trial introduced this year—holding great promise for future treatment options.
What are the most recent clinical trials for afib?
Exciting advancements are being made in the field of atrial fibrillation (afib) treatment, as evidenced by recent clinical trials. One such trial investigates the potential benefits of stellate ganglion block for afib patients, with both Phase 2 and Phase 3 studies currently underway. Another study explores an as-needed rate control approach for managing afib symptoms, showing promise in its Phase 1 stage. Additionally, a Phase 3 trial focuses on evaluating the effectiveness of Asundexian in treating afib. The Colchicine arm study is also at its final phase, aiming to determine if this medication can provide significant relief for individuals with afib. Lastly, a large-scale Phase 4 trial assesses the efficacy and safety profile of oral anticoagulants specifically designed for those living with atrial fibrillation. These ongoing trials offer hope for improved management strategies and enhanced quality of life among afib patients.
What afib clinical trials were recently completed?
Several recent clinical trials have made significant strides in the field of atrial fibrillation (afib) research. In May 2021, St. Vincent Cardiovascular Research Institute successfully completed a trial investigating the effectiveness of Colchicine for this common heart rhythm disorder. Wake Forest University Health Sciences also concluded a trial examining Methohexital in April 2020. Additionally, Allergan's AGN-151607 study reached completion in March 2019, and Population Health Research Institute wrapped up their investigation into Colchicine for afib treatment in February 2018. These studies represent important contributions towards advancing our understanding and management of atrial fibrillation.